Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07467447) titled 'Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight' on March 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).

Primary Sponsor: Hudson Biotech

Condition: Obesity

Intervention: Drug: Retatrutide (LY3437943) Drug: Placebo

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: February 15, 2026

Target Sample Size: 300

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07467447

Published by HT Digita...